Antithrombogenic Coating of Stents Using a Biodegradable Drug Delivery Technology

R. Herrmann; G. Schmidmaier; B. Märkl; A. Resch; I. Hähnel; A. Stemberger; E. Alt

doi:10.1055/s-0037-1614629

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1999; 82(01): 51-57
DOI: 10.1055/s-0037-1614629

Rapid Communication

Schattauer GmbH

Antithrombogenic Coating of Stents Using a Biodegradable Drug Delivery Technology

R. Herrmann

²From the I. Medizinische Klinik, Technische Universität München, Munich, Germany

,

G. Schmidmaier

¹Inst. Exp. Onkologie und Therapieforschung, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

,

B. Märkl

²From the I. Medizinische Klinik, Technische Universität München, Munich, Germany

,

A. Resch

²From the I. Medizinische Klinik, Technische Universität München, Munich, Germany

,

I. Hähnel

²From the I. Medizinische Klinik, Technische Universität München, Munich, Germany

,

A. Stemberger

¹Inst. Exp. Onkologie und Therapieforschung, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

,

E. Alt

²From the I. Medizinische Klinik, Technische Universität München, Munich, Germany

› Institutsangaben

Abstract

Summary

To reduce the thrombogenic properties of coronary artery stents, a biodegradable polylactic acid (PLA) stent coating with an incorporated thrombin inhibitor and a platelet aggregation inhibitor has been developed. In an ex vivo human stasis model, its effect on platelets, plasmatic coagulation and its release characteristics were studied using whole blood. Bare steel and bare gold-surface stents were compared to steel and gold-surface stents coated with PLA (30 kDa) containing 5% polyethyleneglycol (PEG)-hirudin and 1% iloprost, with an empty tube as control. Markers of activated coagulation (prothrombin fragment F_1-2 and thrombin-antithrombin III complex, TAT), were assayed and the release of drugs from the coating was assessed by aPTT and collagen-induced platelet aggregation. Bare steel and gold stents were completely covered by a blood clot, and high levels of coagulation markers (F_1-2 fragment and TAT) were detected. No differences in the thrombogenic properties were found between bare gold or steel stents. Coated stents were free of blood clots and only minor elevations of markers were detected. Release data from in-vitro studies over 90 days showed a gradual release of the drugs with an initial exponential release characteristic for PEG-hirudin, slow release of iloprost and a 10% degradation of the PLA carrier. This drug releasing biodegradable coating effectively reduced thrombus formation independent of the metallic surface.

Volltext

Referenzen

References
1 Fuster V, Falk E, Fallon J, Badimon L, Chesebro J, Badimon J. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate. Thromb Haemost 1995; 74: 552-9.
2 Sheth S, Litvack F, Dev V, Fishbein MC, Forrester JS, Eigler N. Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Circulation 1996; 94: 1733-40.
3 Schwartz S, Reidy M, O’Brien E. Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 1995; 74: 541-51.
4 Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
5 Serruys PW, de JP, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
6 Schatz RA, Baim DS, Leon M. et al. Clinical experience with the Palmaz-Schatz coronary stent: Initial results of a multicenter study. Circulation 1991; 83: 148-61.
7 Hennessy T, Codd M, McCann H, McCarthy C, Sugrue D. Coronary stenting in clinical practice: Patient profile, immediate outcome, clinical and angiographic follow-up in 243 consecutive patients. J Invas Cardiol 1997; 9: 257-62.
8 Schömig A, Neumann FJ, Kastrati A, Schülen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
9 Henry P, Boughalem K, Rinaldi JP, Makowski S, Khalife K, Guermonpres JL, Blanchard D. Use of anti-GP IIb-IIIa in acute thrombosis after intra-coronary stent implantation. Cathet Cardiovasc Diagn 1998; 43: 105-7.
10 Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78: 35-40.
11 Breckwoldt WL, Belkin M, Gould K, Allen M, Connolly RJ, Termin P. Modification of the thrombogenicity of a self-expanding vascular stent. J Invest Surg 1991; 4: 269-78.
12 De SI, Wang K, Wilczek K, Meuleman D, Van AR, Vogel G, Piessens J, Van de Werf F. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation 1997; 95: 1549-53.
13 Bailey SR, Paige S, Lunn A, Palmaz J. Heparin Coating of Endovascular Stents decreases subacute thrombosis in a rabbit model. Circulation 1992; 86: 186
14 Serruys PW, Emanuelsson H, van der Giessen W, Lunn AC, Kiemeney F, Macaya C, Rutsch W, Heyndrickx G, Suryapranata H, Legrand V, Goy JJ, Materne P, Bonnier H, Morice MC, Fajadet J, Belardi J, Colombo A, Gar-cia E, Ruygrok P, de Jaegere P, Morel MA. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. Circulation 1996; 93: 412-22.
15 Carney DH, Mann R, Redin WR, Pernia SD, Berry D, Heggers JP, Hayward PG, Robson MC, Christie J, Fenton IIJW, Glenn KC. Enhancement of incisional wound healing and new vascularization in normal by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest 1992; 89: 1469-744.
16 Stemberger A, Schmidmaier G, Förster C, Alt E, Kohn J, Calatzis A. New antithrombin agents: Potential for coating biomaterials used in cardiopulmonary bypass. In: New Anticoagulants for the Cardiovascular Patient. Pifarre R. ed Philadelphia: Hanley & Belfus, Inc; 1997: 377-86.
17 Hutmacher D, Hürzeler MB, Schliephake H. A review of material properties of biodegradable and bioresorbable polymers and devices for GTR and GBR applications. Int J Oral Maxillofac Implants 1996; 11: 667-78.
18 Born GVR. Quantitative investigations into the aggregation of blood platelets. J Physiol Lond 1962; 162: 67-8.
19 Korn RL, Fisher CA, Stenach N, Jeevanandam V, Addonizio VP. Iloprost reduces procoagulant activity in the extracorporeal circuit. J Surg Res 1993; 55: 433-40.
20 Wasserman K, Hansen JE, Sue DY, Whipp BJ, Casaburi R. Principles of Exercise Testing and Interpretation. Philadelphia: Lea & Febiger; 1994: 20-7.
21 Alt E, Beilharz C, Preter D, Schmidmaier G, Pasquantonio J, Calatzis A, Stemberger A. Antithrombogenic stent coating reduces restenosis in a sheep model. Annals of Hematology 1996; 74 (Suppl II) A112
22 Prietzel K, Pasquantonio J, Fleidner T, Stemberger A, Janczewski M. Inhibition of neointima proliferation with a novel, hirudin, prostacyclin analog eluting stent coating in an animal overstretch model. Circulation 1996; 94: A1522
23 Banning A, Brewer L, Wendt M, Groves PH, Cheadle H, Penny WJ, Crawford N. Local delivery of platelets with encapsulated iloprost to balloon injured pig carotid arteries: effect on platelet deposition and neointima formation. Thromb Haemost 1997; 77: 190-6.
24 Crawford N, Chronos N. Electro-encapsulating drugs within blood platelets: local delivery to injured arteries during angioplasty. Semin Interv Cardiol 1996; 1: 91-102.
25 Schakenraad JM, Hardonk MJ, Feijen J, Molenaar I, Nieuwenhuis P. Enzyme activity toward poly(l-lactic acid) implants. J Biomed Mater Res 1990; 24: 529-45.
26 Bos RRM, Boering G, Rozema FR, Leenslag JW. Resorbable poly(l-lac-tide) plates and screws for the fixation of zygomatic fractures. J Oral Maxillofac Surg 1987; 45: 751-3.
27 Yamawaki T, Shimokawa H, Kozai T, Miyata K, Higo T, Tanaka E, Egashira K, Shiraishi T, Tamai H, Igaki K, Takeshita A. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. JACC 1998; 32: 780-6.
28 Schellhammer F, Berlis A, Bloss H, Pagenstecher A, Schumacher M. Poly-lactic-acid coating for endovascular stents. Preliminary results in canine experimental arteriovenous fistulae. Investigative Radiology 1997; 32: 180-6.
29 Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. JACC 1997; 29: 808-16.
30 Holmes DR, Camrud AR, Jorgenson MA, Edwards WD, Schwartz RS. Polymeric stenting in the porcine coronary artery model: Differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. Journal of the American College of Cardiology 1994; 24: 525-31.
31 Matsuhashi T, Miyachi H, Ishibashi T, Sakamoto K, Yamadera A. In vivo evaluation of a fluorine-acryl-stylene-urethane-silicone antithrombogenic coating material copolymer for intravascular stents. Acad Radiol 1996; 3: 581-8.
32 De SI, Wilczek KL, Verbeken EV, Vandorpe J, Lan PN, Schacht E, De GH, Piessens J. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 1995; 114: 105-14.
33 Fontaine AB, Koelling K, Clay J, Spigos DG, Dos PS, Christoforidis G, Hinkle G, Hill T, Cearlock J, Pozderac R. Decreased platelet adherence of polymer-coated tantalum stents. J Vasc Interv Radiol 1994; 5: 567-72.
34 Schroer K. Prostacyclin (Prostaglandin I₂) and Atherosclerosis. In: The Endothelium in Clinical Practice, Source and Target of Novel Therapies. Rubanyi GM, Dzau VJ. eds New York: Marcel Dekker; 1997: 1-44.
35 Stubbs MT, Bode W. A player of many parts: The spotlight falls on thrombin’s structure. Thrombosis Research 1993; 69: 1-58.
36 Eriksson C, Nygren H. The initial reactions of graphite and gold with blood. J Biomed Mater Res 1997; 37: 130-6.
37 Tanigawa N, Sawada S, Kobayashi M. Reaction of the aortic wall to six metallic stent materials. Acad Radiol 1995; 2: 379-84.
38 Beythien C, Gutensohn K, Bau J, Hamm CW, Schmidmaier G, Alt E, Terres W. Gold coating of coronary stents: A flow cytometric analysis of platelet activation in a pulsed flow model. Thromb Haemost 1997; 105: 426 (abstract).